Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832724 · ClinicalTrials.gov registry record · Phase 2
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT04832724 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 60 participants.
The verdict
NCT04832724, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD. Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. The purpose of this phase 2, open label study is to evaluate whether different doses of RGX-314 from two different formulations (clinical versus eventual commercial formulation) perform the same in humans when delivered by subretinal administration
Interventions
- GENETIC RGX-314
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2024-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04832724
The ClinicalTrials.gov registry entry for NCT04832724 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RGX-314 is the first listed.
NCT04832724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04832724 about?
NCT04832724 is a clinical study titled "RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)". RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD. Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. The purpose of this phase 2, open...
What is the current status of trial NCT04832724?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-02-22. Estimated completion is 2024-03-18.
What interventions are being tested in trial NCT04832724?
The interventions under investigation include: RGX-314 (GENETIC).
Who is sponsoring clinical trial NCT04832724?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.